Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 160 mg/ml; zoster immunoglobulin, quantity: 200 iu - injection, solution - excipient ingredients: water for injections; glycine; human immunoglobulin a - indications as at 8 august 2002 : zoster immunoglobulin is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below: 1. one of the following underlying illnesses or conditions: a. neoplastic disease (leukaemia or lymphoma); b. congenital or acquired immunodeficiency; c. immunosuppressive therapy with steroids or antimetabolites. 2. one of the following types of exposure to chickenpox or shingles patients: a. household contact; b. playmate contact (>1 hour play indoors); c. hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward); d. newborn contact (newborn of mother who had onset of chickenpox <5 days before delivery or within 48 hours after delivery); e. premature infant (>= 28 weeks gestation) whose mother lacks a prior history of chickenpox; f. premature infant (< 28 weeks gestation or <= 1000g) regardless of maternal history. 3. negative or unknown history of chickenpox. 4. if zoster immunoglobulin can be administered within 96 hours after exposure. zoster immunoglobulin, normal immunoglobulin (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. high levels of circulating antibody do not prevent dissemination of infection. zoster immunoglobulin is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.

Israel - English - Ministry of Health

salomon,levin & elstein ltd - fluorouracil - solution for injection - fluorouracil 50 mg/ml - fluorouracil - palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas, in selected patients considered incurable by surgery or other means.as leucovorin-fluorouracil chemotherapy combination for cancer treatment.

Israel - English - Ministry of Health

abic marketing ltd, israel - fluorouracil - solution for injection - fluorouracil 50 mg/ml - fluorouracil - fluorouracil - palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas, in selected patients considered incurable by surgery or other means.as leucovorin-fluorouracil chemotherapy combination for cancer treatment.

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - horse gamma globulin - injection - 50 mg/ml - horse gamma globulin 50 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - methotrexate - solution for injection in pre-filled syringe - 25 mg/ml - antineoplastic and immunomodulating agents, antimetabolites, folic acid analogues - active rheumatoid arthritis in adult patients; polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to non-steroidal antiinflammatory drugs (nsaids) has been inadequate; severe forms of psoriasis vulgaris, particularly of the plaque type, which cannot be sufficiently treated with conventional therapy such as phototherapy, puva, and retinoids, and severe psoriatic arthritis

United Kingdom - English - myHealthbox

hameln pharmaceuticals ltd - methotrexate - solution for injection in pre-filled syringe - 25 mg/ml - antineoplastic and immunomodulating agents, antimetabolites, folic acid analogues - active rheumatoid arthritis in adult patients where treatment with disease modifying antirheumatic drugs (dmard) is indicated; polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate; severe forms of psoriasis vulgaris, particularly of the plaque type, which cannot be sufficiently treated with conventional therapy such as phototherapy, puva, and retinoids, and severe psoriatic arthritis

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - hydroxocobalamin acetate (unii: s535m27n3q) (hydroxocobalamin - unii:q40x8h422o) - hydroxocobalamin 1000 ug in 1 ml - - pernicious anemia, both uncomplicated and accompanied by nervous system involvement. pernicious anemia, both uncomplicated and accompanied by nervous system involvement. - dietary deficiency of vitamin b12 , occurring in strict vegetarians and in their breast-fed infants. (isolated vitamin b12 deficiency is very rare). dietary deficiency of vitamin b12 , occurring in strict vegetarians and in their breast-fed infants. (isolated vitamin b12 deficiency is very rare). - malabsorption of vitamin b12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin b12 absorption. these conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). folate deficiency in these patients is usually more severe than vitamin b12 deficiency. malabsorption of vitamin b12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin b12 absorption. these conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). folate deficiency in these patients is usually more severe than vitamin b12 deficiency. - inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). total gastrectomy always produces vitamin b12 deficiency. structural lesions leading to vitamin b12 deficiency include regional ileitis, ileal resections, malignancies, etc. inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). total gastrectomy always produces vitamin b12 deficiency. structural lesions leading to vitamin b12 deficiency include regional ileitis, ileal resections, malignancies, etc. - competition for vitamin b12 by intestinal parasites or bacteria. the fish tapeworm (diphyllobothrium latum) absorbs huge quantities of vitamin b12 and infested patients often have associated gastric atrophy. the blind-loop syndrome may produce deficiency of vitamin b12 or folate. competition for vitamin b12 by intestinal parasites or bacteria. the fish tapeworm (diphyllobothrium latum) absorbs huge quantities of vitamin b12 and infested patients often have associated gastric atrophy. the blind-loop syndrome may produce deficiency of vitamin b12 or folate. - inadequate utilization of vitamin b12 . this may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. inadequate utilization of vitamin b12 . this may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. - for the schilling test. for the schilling test.

Australia - English - Department of Health (Therapeutic Goods Administration)

vaccinia virus -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - mercaptopurine monohydrate 50mg; mercaptopurine monohydrate 50mg - tablet - 50 mg - active: mercaptopurine monohydrate 50mg excipient: lactose monohydrate magnesium stearate maize starch stearic acid active: mercaptopurine monohydrate 50mg excipient: lactose monohydrate magnesium stearate maize starch stearic acid - puri-nethol is indicated for the treatment of acute leukaemia. it may be utilised in remission induction and is particularly indicated for maintenance therapy in: · acute lymphoblastic leukaemia; · acute myelogenous leukaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - zoster immunoglobulin, human 100 iu/ml (immunoglobulin ex nz) - solution for injection - 200 iu/2ml - active: zoster immunoglobulin, human 100 iu/ml (immunoglobulin ex nz) excipient: glycine - zoster immunoglobulin-vf is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below: 1. one of the following underlying illnesses or conditions: a. neoplastic disease (leukaemia or lymphoma) b. congenital or acquired immunodeficiency c. immunosuppressive therapy with steroids or antimetabolites. 2. one of the following types of exposure to chickenpox or shingles patients: a. household contact b. playmate contact (> 1 hour play indoors) c. hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward) d. newborn contact (newborn of mother who had onset of chickenpox < 5 days before delivery or within 48 hours after delivery) e. premature infant (> 28 weeks gestation) whose mother lacks a prior history of chickenpox f. premature infant (< 28 weeks gestation or < 1000g) regardless of maternal history. 3. negative or unknown prior history of chickenpox. 4. if zoster immunoglobulin-vf can be administered within 96 hours after exposure. zoster immunoglobulin-vf, normal immunoglobulin-vf (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. high levels of circulating antibody do not prevent dissemination of infection. zoster immunoglobulin-vf is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.